Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658114 | 0.94 | SPR (0.42) | SPRNR4A2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL14215657 | 0.90 | KDM4E (0.46) | SPRNR4A2IGF1RPDGFRBKIT | |
| SCHEMBL12658220 | 0.89 | SPR (0.43) | SPRNR4A2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL14188730 | 0.88 | NR4A2 (0.54) | SPRNR4A2IGF1RPDGFRBKIT | |
| SCHEMBL12658130 | 0.88 | NR4A2 (0.51) | NR4A2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12658205 | 0.83 | NR4A2 (0.44) | NR4A2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Lynamicin B SCHEMBL12658014 | 0.83 | NR4A2 (0.55) | NR4A2KDM4EMEN1KMT2AMTNR1A | |
| SCHEMBL14188735 | 0.82 | NR4A2 (0.52) | NR4A2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| Lynamicin A SCHEMBL12658027 | 0.81 | NR4A2 (0.61) | NR4A2KDM4EMEN1KMT2AMTNR1A | |
| SCHEMBL14188729 | 0.80 | KDM4E (0.46) | SPRNR4A2IGF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375129-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375129-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070149601-A1 | Bis-indole pyrroles useful as antimicrobials agents | PRIVATE LIFE BIOMED AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149601-A1 | Bis-indole pyrroles useful as antimicrobials agents | PRIVATE LIFE BIOMED AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-7166634-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166634-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149601-A1 | Bis-indole pyrroles useful as antimicrobials agents | IDO1, IDO2, TPH1 | SPR 676/4885NR4A2 4802/4885PRKAB2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.